E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Hepatocellular Carcinoma, non-resectable |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 14.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10019828 |
E.1.2 | Term | Hepatocellular carcinoma non-resectable |
E.1.2 | System Organ Class | 100000004864 |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The principal objective is to determine whether addition of sorafenib to TransArterial ChemoEmbolisation (TACE) performed with doxorubicin eluting beads prolongs progression free survival in patients with unresectable Hepatocellular Carcinoma (HCC) compared to TACE alone. TACE is standard treatment for patients with HCC that cannot be removed by surgery. This procedure involves blocking the blood vessel that supplies the tumour with small particles and killing it by starving it of oxygen. These particles are loaded with the chemotherapy drug doxorubicin which is delivered directly to the tumour and may increase effectiveness of the procedure. Sorafenib is a relatively new anticancer treatment which is approved for use in the treatment of HCC. It works by slowing down growth of cancer cells and also slows the rate of new vessel formation on which tumour growth depends. As they work in different and complementary ways, combining the two treatments may be more effective than TACE alone. |
|
E.2.2 | Secondary objectives of the trial |
As stated, the principal objective looks specifically at progression free survival which is defined as the interval between the date of randomisation and the date of progression or death from any cause. A secondary objective of this study is to determine whether the combination therapy prolongs either the time to progression alone or the overall survival of patients. Both factors are of important significance but would require a larger sample size to form the principal objective. A realistically achievable recruitment target is crucial to a successful study and progression free survival was considered to be a suitable surrogate.
The study will also assess whether the combination therapy has acceptable toxicity, the affect on disease response and the impact on patient Quality of Life. The study will measure whether it reduces the frequency for repeat TACE as measured by the number of TACE procedures performed in 12 months following randomisation. |
|
E.2.3 | Trial contains a sub-study | Yes |
E.2.3.1 | Full title, date and version of each sub-study and their related objectives |
The TACE-2 Quality of Life (QoL) substudy is being run alongside the main trial and details are in the main trial protocol. The QoL substudy will assess general & hepatocellular specific aspects of quality of life using EORTC QLQC30 version 3, EORTC QLQHCC18 & EuroQoL (EQ5D) questionnaire. |
|
E.3 | Principal inclusion criteria |
Histological or cytological diagnosis or meet the AASLD criteria (Appendix 1) for diagnosis of HCC and at least one uni-dimensional lesion measurable according to the RECIST criteria by CT-scan or MRI (Appendix 2)
Not a candidate for surgical resection or liver transplant
Aged 18 years and estimated life expectancy >3 months
ECOG performance status 1 (Appendix 3)
Adequate haematological function Hb 9g/L, absolute neutrophil count 1.5x109/L, platelet count 60x109/L
Bilirubin ≤50 μmol/L, AST or ALT ≤5 x ULN, ALP <4 x ULN
Adequate renal function; Creatinine ≤1.5 x ULN
INR ≤1.5
Amylase <2 x ULN
Child-Pugh cirrhosis A (score must be ≤6) (Appendix 4)
Left Ventricular Ejection fraction ≥45%
Women of child-bearing potential should have a negative pregnancy test prior to study entry. Both men and women must be using an adequate contraception method, which must be continued for 3 months after completion of treatment
Written informed consent |
|
E.4 | Principal exclusion criteria |
Extrahepatic metastasis
Prior embolisation, systemic or radiation therapy for HCC
Any contraindications for hepatic embolisation procedures including portosystemic shunt, hepatofugal blood flow, known severe atheromatosis
Investigational therapy or major surgery within 4 weeks of trial entry
Any ablative therapy (RFA or PEI) for HCC (this should not exclude patients if target lesion(s) have not been treated and occurred >6 weeks prior to study entry)
History of bleeding within the past 4 weeks
Child-Pugh cirrhosis C and B with score 7 (Appendix 4)
Hepatic encephalopathy
Ascites refractory to diuretic therapy
Documented occlusion of the hepatic artery or main portal vein
Hypersensitivity to intravenous contrast agents
Active clinically serious infection > grade 2 NCI-CTC version 4 (Appendix 5)
Pregnant or lactating women
Known history of HIV infection
Protocol v76.0,28th January 2013 2nd October 2012 Page 7 of 84 Cancer Research UK Clinical Trials Unit
History of second malignancy except those treated with curative intent more than three years previously without relapse and non-melanotic skin cancer or cervical carcinoma in situ
Evidence of severe or uncontrolled systemic diseases, cardiac arrhythmias (requiring anti-arrhythmic therapy or pace maker), uncontrolled hypertension, congestive cardiac failure >NYHA class 2 (Appendix 6), MI within 6 months, prolonged QT/QTc >450ms, or laboratory finding that in the view of the investigator makes it undesirable for the patient to participate in the trial
Psychiatric or other disorder likely to impact on informed consent
Patient is unable and/or unwilling to comply with |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Progression Free Survival |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Primary endpoint assessments are performed at the ten-week assessment and then 12-weekly thereafter. |
|
E.5.2 | Secondary end point(s) |
Overall Survival
Time to Progression
Toxicity
Disease Control (CR+PR+SD)
QoL
Number of TACE procedures performed during 12 months following randomisation. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Secondary endpoint assessments are performed at the followin timepoints:
the day of randomisation; assessment during 72 hours pre-TACE; follow up at seven days post-TACE; ten-week follow up assessment and six-weekly thereafter. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 1 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 30 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
For regulatory and ethical purposes, the trial will be closed to recruitment when 206 patients have been recruited to
each treatment arm. The study will continue for one year after the last patient has been recruited. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 3 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 5 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |